US health regulators said Thursday they are barring imported drugs from an overseas factory operated by Ranbaxy Laboratories Indias largest drugmaker due to quality control violations The Food and Drug Administration ban effectively stops the company from shipping drugs and raw ingredients from its Toansa plant in the Punjab province A Jan  inspection by FDA staffers uncovered factory workers retesting drug ingredients that had failed quality testing in an apparent effort to return positive results Those practices and others found at the plant violate manufacturing standards for drugmakers that do business in the US  The FDA is committed to ensuring that the drugs American consumers receive  no matter where they are produced  meet quality standards and are safe and effective said FDA compliance director Carol Bennett  Ranbaxy did not immediately respond to requests for comment Thursday  Ranbaxy will be required to hire an outside inspector to review the plant and certify that it is meeting US quality standards before the ban can be lifted  In September the FDA placed a similar hold on imports from Ranbaxys Mohali facility Both actions were taken under a  legal settlement with the FDA which subjects Ranbaxy to extra scrutiny and inspections to improve its drug production  With annual revenue of more than  billion Ranbaxy is the leading drugmaker in Indias  billion generic pharmaceutical industry but it has faced penalties from US regulators for years  In May the companys American subsidiary agreed to pay  million in fines and penalties for selling adulterated drugs and lying to federal regulators the largest financial penalty against a generic drug company for violations of the Federal Food Drug and Cosmetic Act which prohibits the sale of impure drugsÂ 